OS by 2017 ELN risk group, by type of postremission therapy (conventional consolidation vs allogeneic HCT in CR1), and by treatment arm (placebo vs midostaurin). Simon-Makuch plots illustrating the influence of allogeneic HCT as a time-dependent variable: patients who receive an allogeneic HCT move from the red to the blue curve at the time that the allogeneic HCT is performed. (A) ELN favorable-risk group: placebo arm (left panel) and midostaurin arm (right panel). (B) ELN intermediate-risk group: placebo arm (left panel) and midostaurin arm (right panel). (C) ELN adverse-risk group: placebo arm (left panel) and midostaurin arm (right panel).